New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 10, 2014
14:23 EDTPIP, SIGAPharmAthene awarded lump sum expectation damages from SIGA Technologies
PharmAthene (PIP) announced that on August 8, the Delaware Court of Chancery issued a Memorandum Opinion and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA Technologies (SIGA) smallpox antiviral, Tecovirimat. In addition, the Court ordered SIGA to pay prejudgment interest and varying percentages of PharmAthene's reasonable attorneys' and expert witness fees."We are extremely pleased by the Chancery Court's ruling to award PharmAthene lump sum expectancy damages that it suffered due to SIGA's breach of contract," said Eric I. Richman, President and CEO. "We look forward to working with our damages expert to calculate the lump sum damage amounts in accordance with the Court's decision and its instructions in the accompanying order."
News For PIP;SIGA From The Last 14 Days
Check below for free stories on PIP;SIGA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
09:25 EDTPIP, SIGAOn The Fly: Pre-market Movers
Subscribe for More Information
06:51 EDTSIGASIGA Technologies files petition for relief to supply Tecovirimat
Subscribe for More Information
September 11, 2014
07:25 EDTPIPAegis to hold a conference
Subscribe for More Information
September 10, 2014
09:07 EDTPIPPharmAthene awarded $28.1M contract by NIAID
Subscribe for More Information
September 9, 2014
09:08 EDTPIPPharmAthene presented non-clinical animal data on SparVax anthrax vaccine
PharmAthene announced that recent non-clinical animal data from its SparVax anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC, in Washington, DC. In a poster presentation Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented an overview of non clinical animal studies of SparVax showing, among other things, that it can induce dose-dependent protective immunity in the established rabbit model for inhalational anthrax, and was statistically non-inferior to the currently licensed anthrax vaccine, BioThrax, when comparing survival and toxin neutralization assay results from the nonclinical anthrax aerosol challenge model.
September 8, 2014
10:14 EDTPIPPharmAthene, Nanotherapeutics form alliance
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use